On April 9, 2021, Chemclin Diagnostics Corporation (stock code 688468) successfully listed on SSESTARMarket of the Shanghai Stock Exchange. On the first day of listing, the opening price was RMB 20, an increase of 179.72% from the issue price of RMB 7.15 per share, and the market value once exceeded RMB 8.6 billion.

At the listing ceremony, Li Lin, Chairman and General Manager of Chemclin Diagnostics, said: “Through this public offering, Chemclin Diagnostics will enter a new stage of development. Chemclin Diagnostics will use this initial listing as an opportunity, with the power of the capital market, continuously increase investment in product research and development. At the same time, we will also make the "world-class well-known in vitro diagnostic enterprise" as the direction of our efforts, create more value, return the majority of investors and the society!"

Established in 2007, Chemclin Diagnostics is one of the earliest companies specializing in the development of clinical immunological diagnostic products in China. The company’s products are LiCA series diagnostic reagents based on light-induced chemiluminescence method and CC series diagnostic reagents and instruments based on enzymatic chemiluminescence method, which are mainly used in infectious disease markers, tumor markers, thyroid hormones, reproductive endocrine hormones, and myocardial markers And the detection of inflammation, etc.